ADC Therapeutics SA

ADC Therapeutics develops cancer drugs using a technology called antibody drug conjugates, which attach cancer-fighting chemicals to antibodies that target specific cells. The company's main product is ZYNLONTA, a drug approved in the United States, Europe, and China to treat a type of blood cancer called diffuse large B-cell lymphoma in patients who have already tried other treatments. ADC Therapeutics is testing ZYNLONTA in additional patient groups and earlier stages of treatment, as well as developing other experimental drugs for different blood cancers. The company is based in Switzerland…